NEW YORK, Feb. 21 (GenomeWeb News) - LifeSpan BioSciences has sold "most of its existing catalog" of antibodies to Medical and Biological Laboratories International, LifeSpan confirmed today.
The Massachusetts-based subsidiary of Nagoya, Japan-based MBL bought 921 antibodies to about 400 different protein targets, including 800 GPCR antibodies.
"MBL has a broader reach in terms of selling this product," LifeSpan CEO Joseph Brown said.
Brown said LifeSpan plans to continue developing antibodies to gene-target proteins and will consider future distribution deals with MBL.
Financial details of the deal were not available.